131 related articles for article (PubMed ID: 38426611)
1. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
[TBL] [Abstract][Full Text] [Related]
2. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD.
Tang LJ; Li G; Eslam M; Zhu PW; Chen SD; Leung HH; Huang OY; Wong GL; Zhou YJ; Karsdal M; Leeming DJ; Jiang P; Wang C; Yuan HY; Byrne CD; Targher G; George J; Wong VW; Zheng MH
Hepatol Int; 2023 Feb; 17(1):190-201. PubMed ID: 36152131
[TBL] [Abstract][Full Text] [Related]
3. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.
Tang LJ; Ma HL; Eslam M; Wong GL; Zhu PW; Chen SD; Leeming DJ; Karsdal M; Li G; Huang OY; Leung HH; Zhou YJ; Feng Q; Jiang P; Gao LM; Byrne CD; Targher G; George J; Wong VW; Zheng MH
Metabolism; 2022 Mar; 128():154958. PubMed ID: 34958817
[TBL] [Abstract][Full Text] [Related]
4. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
Daniels SJ; Leeming DJ; Eslam M; Hashem AM; Nielsen MJ; Krag A; Karsdal MA; Grove JI; Neil Guha I; Kawaguchi T; Torimura T; McLeod D; Akiba J; Kaye P; de Boer B; Aithal GP; Adams LA; George J
Hepatology; 2019 Mar; 69(3):1075-1086. PubMed ID: 30014517
[TBL] [Abstract][Full Text] [Related]
5. PRO-C3, liver fibrosis and CKD: The plot thickens.
Lonardo A
Liver Int; 2024 May; 44(5):1126-1128. PubMed ID: 38634694
[No Abstract] [Full Text] [Related]
6. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
7. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
8. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
9. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
10. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.
Eslam M; Wong GL; Hashem AM; Chan HL; Nielsen MJ; Leeming DJ; Chan AW; Chen Y; Duffin KL; Karsdal M; Schattenberg JM; George J; Wong VW
Am J Gastroenterol; 2021 May; 116(5):984-993. PubMed ID: 33252454
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
13. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.
Su W; Chen M; Xiao L; Du S; Xue L; Feng R; Ye W
Front Public Health; 2022; 10():1047794. PubMed ID: 36420005
[TBL] [Abstract][Full Text] [Related]
14. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
[TBL] [Abstract][Full Text] [Related]
16. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
[TBL] [Abstract][Full Text] [Related]
17. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD.
Li Y; Wu S; Gao J; Zhang Y; Zuo Y; Tian X; Chen S; Xing A; Wang A; He Y
Am J Kidney Dis; 2024 Apr; 83(4):477-488. PubMed ID: 37838141
[TBL] [Abstract][Full Text] [Related]
18. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts.
Zhang Y; Zhang T; Liu Y; Bai S; Jiang J; Zhou H; Luan J; Cao L; Lv Y; Zhang Q; Liu L; Sun S; Wang X; Zhou M; Jia Q; Song K; Zhang H; Chang Q; Fan X; Ding Y; Chen L; Zhao Y; Niu K; Xia Y
Diabetes Metab Syndr; 2023 Oct; 17(10):102873. PubMed ID: 37804689
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
[TBL] [Abstract][Full Text] [Related]
20. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
